Brukinsa (zanubrutinib) Approved in the U.S. for Chronic Lymphocytic Leukemia

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. — January 19, 2023 –(BUSINESS WIRE)– BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has…Original Article